In the past decades, a range of structurally different compounds ( Figure 2 ) as ALR2 inhibitors (ARIs) have been reported. However, epalrestat of the carboxylic acid ( Figure 2 ) is still the only ARI in clinical use as a drug in Japan and more recently in China and India [6] [7] because of the adverse pharmacokinetics, toxic side effects or low efficacy. Most of the typical carboxylic acid ARIs showed potent in vitro activity but their effectiveness decreases in vivo. In their turn, the cyclic imide ARIs often develop toxicity and exhibit some side effects [8] . Thus, more effort into the development of a larger variety of ARIs that inhibit ALR2 strongly and specifically is still needed. We have recently designed a number of potent ARIs based on the scaffolds of benzothiadiazine 1,1-dioxide and quinoxalinone. The present study is focusing on benzothiadiazine-based nitro derivatives during the course of searching for non-carboxylic acid ARIs. Here, we report their preparation, aldose reductase inhibition activity, and docking studies. All reactions were routinely checked by TLC on silica gel Merck 60F254. NMR spectra were recorded on a Bruker Advance 400 spectrometer (Bruker (Beijing) Technologies & Services Co., Ltd), while 13 C NMR spectra were recorded at 100 MHz in DMSO-d 6 .
ALR2 inhibition
All newly synthesized nitro derivatives of 1,2-benzothiazine 1,1-dioxide were tested for their potential inhibitory effect on ALR2 isolated from rat lenses. Most of the compounds showed good activity in the ALR2 inhibition as shown in Table 1 . Among them, 7a was the most active compound with an IC 50 value of 4.6 µM. In contrast, the nitro derivative 11a was the least effective with an inhibition ratio of 9.34% at a concentration of 10 μM. It is noteworthy that the attachment of nitro group to the compound 4 leading to compounds 7a-b showed significant effect on the inhibitory activity of the ALR2 inhibition, and even compound 7a was more active than the carboxylic acid compound 6. However, nitro derivatives of 9a-b and 11a-b all showed low activity. Thus, nitro derivatives based on benzothiazine 1,1-dioxide have remained optimized. 
Molecular docking
Molecular modeling was performed to get a better understanding of the ALR2 inhibitory potency of the newly synthesized compounds at a molecular level and to propose a binding mode, which used Molegro Virtual Docker, version 5.0 (CLC bio, Aarhus, Denmark). Compound 7a, the most active as described above, was docked into the binding pocket of the human ALR2/NADP+/lidorestat complex (PDB entry code 1Z3N) as shown in Figure 3 . Docking results suggest that the inhibitor 7a is tightly bound in the active site of ALR2. As an electronic acceptor, nitryl at the C6 position of benzothiadiazine 1,1-dioxide also joint connection with the hydroxy group through tight hydrogen bonds. Therefore, further studies about nitro derivatives of benzothiadiazine 1,1-dioxide as aldose reductase inhibitors is necessary and meaningful.
CONCLUSION
New nitro-benzothiadiazine 1,1-dioxide derivatives were synthesized, and some of them showed significant inhibitory activity against ALR2 and potential for the development of effective noncarboxylic acid ARIs.
